



Kongeriget Danmark

Patent application No.: PA 2003 01570

Date of filing: 24 October 2003

Applicant:
(Name and address)
Gastrotech Pharma A/S
Østergade 5, 3. sal
DK-1100 København K
Denmark

Title: Use of a secretagogue for the treatment of lipodystrophy

IPC: -

This is to certify that the attached documents are exact copies of the above mentioned patent application as originally filed.



Patent- og Varemærkestyrelsen
Økonomi- og Erhvervsministeriet

31 January 2006


Susanne Morsing



PATENT- OG VAREMÆRKESTYRELSEN

P 800 DK01

1

Use of a secretagogue for the treatment of lipodystrophy

All patent and non-patent references cited in the application, or in the present application, are also hereby incorporated by reference in their entirety.

5

Field of invention

The present invention relates to the use of a secretagogue, such as a ghrelin-like compound for the production of medicament for the treatment or prevention of 10 lipodystrophy as well as to a method of treating or preventing lipodystrophy in an individual in need thereof by administering a secretagogue, such as a ghrelin-like compound.

15

Background of invention

20

Lipodystrophic syndromes encompass a heterogeneous group of rare disorders characterized by partial or generalized loss of adipose tissue depots [Am J Med 2000; 108, 143-152]. There are several different types of lipodystrophies and the degree of fat loss may vary from very small depressed areas to near complete absence of adipose tissue. Some patients may have only cosmetic problems while others may also have severe metabolic complications such as dyslipidemia, hepatic steatosis, and severe insulin resistance [Trend Endo Meta 2000;11:410-416]. These disorders can either be inherited (familial or genetic lipodystrophies) or can occur secondary to various types of illnesses or drugs (acquired lipodystrophies).

25

Inherited lipodystrophies are caused by mutations (alterations or blips) in a gene. Several genes responsible for different types of inherited lipodystrophies have been identified. These include AGPAT2 (1-acylglycerol-3-phosphate-O-Acyltransferase 2), BSCL2 (Berardinelli-Seip congenital lipodystrophy 2) in Congenital Generalized Lipodystrophy (CGL), Lamin A/C (LMNA) gene in Familial Partial Lipodystrophy Dunnigan variety (Familial partial lipodystrophy), and PPARG (peroxisome proliferator-activated receptor gamma) gene in familial partial lipodystrophy. Several other candidate genes are currently under investigation for other varieties of inherited lipodystrophies.

P 800 DK01

2

Acquired lipodystrophies are: HAART/HIV-induced Lipodystrophy in HIV-infected patients (LD-HIV), Acquired Generalized Lipodystrophy (AGL), Acquired Partial Lipodystrophy (APL) and localized lipodystrophy. Acquired lipodystrophies do not 5 have a direct genetic basis. Rather, many mechanisms may be involved. One such mechanism may be an autoimmune response that destroys normal fat cells.

HAART/HIV-induced Lipodystrophy has become the most common acquired form of 10 generalized Lipodystrophy. The overall incidence of these physical abnormalities is about 50% after 12-18 month of therapy with protease inhibitors. The difference between the present reports range from 18% to 83% percent due to confounding factors such as type and duration of the retroviral therapy. It has been suggested that the lipodystrophy syndrome associated with protease inhibitors may be due to 15 partial analogy between lipid and adipocyte regulatory proteins and the catalytic site of HIV-1 protease to which the protease inhibitors bind (Carr et al Lancet 1998, 351 1881-83).

Localized lipodystrophies are defined as a localized loss of subcutaneous fat from 20 small areas or from parts of a limb. There may be single or multiple lesions. It is characterized by depressed areas corresponding to the loss of subcutaneous fat. In some cases, it may be associated with tender, painful nodules in the skin. Usually, it occurs in diabetic patients at the site of insulin injections. In some patients, fat loss occurs from areas where pressure is applied frequently. For example, pressing thigh against a make-up table.

25
The patogenesis of lipodystrophy is largely unknown. However accumulating evidences point at mitochondrial defect as central for an increased induction of apoptosis in the adipocytes (6). Several proteins encoded by HIV-1 trigger apoptosis by inducing permeabilization of the mitochondrial membrane. Several nucleoside analogs used clinically in the treatment of HIV-1 inhibit the replication of mitochondrial DNA (mtDNA) and/or increase the frequency of mtDNA mutations. Both of these 30 factors may cause severe mitochondriopathy and contribute to lipodystrophy.

P 800 DK01

3

- The metabolic consequences of lipodystrophy are highly important for the general health and the survival. The fact that insulin resistance and the consequent progression to diabetes can result from either obesity or lipodystrophy reflects the crucial role of adipose tissue in carbohydrate and lipid metabolism. In the absence of adequate adipocyte capacity, excess calories cannot be diverted to their normal storage depot; instead they accumulate as increased triglyceride stores in liver, in skeletal and cardiac muscle, and in the pancreatic β cell. This extra-adipose lipid accumulation, through as yet unclear means, is associated with impaired insulin action and, often, diabetes.
- In addition to their passive role as storage depots, normal adipocytes secrete a number of peptides ("adipokines") that may influence insulin sensitivity and/or energy balance (Kahn JCI and TEM 2002). These include potential insulin sensitizers, such as leptin and Acrp30 (also known as adiponectin), and insulin antagonists, including TNF- α , IL-6, and possibly resistin. The insulin resistance of lipodystrophy may therefore be the result of disturbed lipid fluxes and/or abnormalities of adipokine secretion.
- Therapy with rhGH has been reported to cause reduction in the size of 'buffalo hump' and truncal fat in a small number of patients. However, fat loss and lipid abnormalities did not improve and blood glucose control worsened.
- Ghrelin is a bioactive peptide which originally was described to be involved in the control of GH secretion but later found to be a major regulator of appetite, food intake and energy homeostasis (1;2). As many other bioactive peptides ghrelin probably act both as a hormone, a paracrine substance and as a neurotransmitter.
- The story of ghrelin, its receptor and synthetic compounds acting through this receptor unraveled in a unique "reverse" order. In the eighties a synthetic hexapeptide from a series of opioid-like peptides was found to be able to release growth hormone (GH) from isolated pituitary cells (3). Since this action was independent of the growth hormone releasing hormone (GHRH) receptor, several pharmaceutical companies embarked upon drug discovery projects based on this hexa-peptide GH secretagogue (GHS) and its putative receptor. Several series of potent and efficient peptide as well as non-peptide GH secretagogues were consequently described in the mid nineties (4-6). However, first several years later was the receptor through which these artificial GH secretagogues acted eventually cloned and shown to be a

P 800 DK01

4

member of the 7TM G protein coupled receptor family (7;8). But, first in 1999 was the endogenous ligand for this receptor the hormone ghrelin finally discovered (9). The main site for ghrelin production is the stomach, where the peptide is found in classical endocrine cells in the gastric mucosa.

5

Summary of Invention

The present invention relates to the use of a secretagogue, in particular a ghrelin-like compound, including human ghrelin, in the treatment or prophylaxis of 10 lipodystrophy, whether acquired or congenital, local or generalized.

In a preferred embodiment the invention relates to the use of a ghrelin-like compound for the preparation of a medicament for the treatment or prophylaxis of lipodystrophy, wherein the ghrelin-like compound comprises a structure defined by formula I

$Z^1 - (X^1)_m - (X^2) - (X^3)_n - Z^2$, wherein

20 Z^1 is an optionally present protecting group
each X^1 is independently selected from an amino acid, wherein said amino acid is selected from naturally occurring and synthetic amino acids,

25 X^2 is any amino acid selected from naturally occurring and synthetic occurring amino acids, said amino acid being modified with a bulky hydrophobic group, preferably an acyl group, or a fatty acid,

each X^3 is independently selected from an amino acid, wherein said amino acid is selected from naturally occurring and synthetic amino acids,

30 wherein one or more of X^1 and X^3 optionally may be modified by a bulky hydrophobic group, preferably an acyl group, or a fatty acid,

35 Z^2 is an optionally present protecting group.

P 800 DK01

5

m is an integer in the range of from 1-10

n is 0 or an integer in the range of from 1-35.

- 5 Accordingly, the term "ghrelin-like compound" includes the naturally occurring 28 aa human ghrelin, the amino acid of which is shown in SEQ ID NO: 1, as well as the naturally occurring 27 aa human ghrelin, the amino acid of which is shown in SEQ ID NO: 2. Thus, the present invention relates to the use of ghrelin or a peptide homologous thereto. Ghrelin is described by Kojima in Nature (1999), vol. 402, 656-
10 660.

The present invention significantly lowers the risk of developing lipodystrophy, independent of the cause, such as independent of the particular therapeutic cause of, or therapeutic factor contributing to, the lipodystrophy. Hence, the present
15 invention also extends to treatment of patients with HIV/AIDS by means of antiretroviral agents. For convenience, the term "antiretroviral therapy" is used herein to refer to the treatment of HIV/AIDS in patients by means of antiretroviral agents generally including combinations of such agents as is typically the case.

20 **Detailed description of the invention**

Definitions

- 25 **Affinity:** the strength of binding between receptors and their ligands, for example between an antibody and its antigen.

30 **Amino Acid Residue:** An amino acid formed upon chemical digestion (hydrolysis) of a polypeptide at its peptide linkages. The amino acid residues described herein are preferably in the "L" Isomeric form. However, the amino acid encompasses every amino acid such as L-amino acid, D-amino acid, alpha -amino acid, beta -amino acid, gamma -amino acid, natural amino acid and synthetic amino acid or the like as long as the desired functional property is retained by the polypeptide. NH₂ refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide. In
35

P 800 DK01

6

keeping with standard polypeptide, abbreviations for amino acid residues are shown
in the following Table of Correspondence:

TABLE OF CORRESPONDENCE

	SYMBOL		
	1-Letter	3-Letter	AMINO ACID
5	Y	Tyr	tyrosine
	G	Gly	glycine
	F	Phe	phenylalanine
10	M	Met	methionine
	A	Ala	alanine
	S	Ser	serine
	I	Ile	isoleucine
	L	Leu	leucine
15	T	Thr	threonine
	V	Val	valine
	P	Pro	proline
	K	Lys	lysine
	H	His	histidine
20	Q	Gln	glutamine
	E	Glu	glutamic acid
	Z	Glx	Glu and/or Gln
	W	Trp	tryptophan
	R	Arg	arginine
25	D	Asp	aspartic acid
	N	Asn	asparagine
	B	Asx	Asn and/or Asp
	C	Cys	cysteine
	X	Xaa	Unknown or other

30 It should be noted that all amino acid residue sequences represented herein by formulae have a left-to-right orientation in the conventional direction of amino terminus to carboxy terminus. In addition, the phrase "amino acid residue" is broadly defined to include the amino acids listed in the Table of Correspondence and modified and non-naturally occurring amino acids. Furthermore, it should be noted that a dash at
35

P 800 DK01

7

the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino acid residues or a covalent bond to an amino-terminal group such as NH₂ or acetyl or to a carboxy-terminal group such as COOH.

5

BMI measures your height/weight ratio. It is determined by calculating weight in kilograms divided by the square of height in meters. The BMI "normal" range is 19-22.

10

Concentration equivalent: A concentration equivalent is an Equivalents dosage being defined as the dosage of a ghrelin-like compound having in vitro and/or in vivo the same response as evaluated from a dosage-response curve as wild-type ghrelin.

15

Dissociation constant, Kd: a measure to describe the strength of binding (or affinity or avidity) between receptors and their ligands, for example an antibody and its antigen. The smaller Kd the stronger binding.

20

Fusion Polypeptide: A polypeptide comprised of at least two polypeptides and a linking sequence to operatively link the two polypeptides into one continuous polypeptide. The two polypeptides linked in a fusion polypeptide are typically derived from two independent sources, and therefore a fusion polypeptide comprises two linked polypeptides not normally found linked in nature.

25

Ghrelin: a polypeptide as described in Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K 1999 Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-660. Human 28 aa ghrelin has the amino acid of SEQ ID NO: 1.

30

GHS: growth hormone secretagogue

GHS-R 1a: the receptor for GHS. GHS-R 1a is also denoted GHS 1a.

HAART: Highly active antiretroviral therapy.

P 800 DK01

8

Immunologically distinct: The phrase immunologically distinct refers to the ability to distinguish between two polypeptides on the ability of an antibody to specifically bind one of the polypeptides and not specifically bind the other polypeptide.

5 **Individual:** A living animal or human in need of susceptible to a condition, in particular a cachectic condition as defined herein. In preferred embodiments, the subject is a mammal, including humans and non-human mammals such as dogs, cats, pigs, cows, sheep, goats, horses, rats, and mice. In the most preferred embodiment, the subject is a human.

10 **Isolated:** Is used to describe the various ghrelin-like compounds, polypeptides and nucleotides disclosed herein, that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified.

20 **Modified amino acid:** an amino acid wherein an arbitrary group thereof is chemically modified. In particular, a modified amino acid chemically modified at the alpha - carbon atom in an alpha -amino acid is preferable.

25 **Monoclonal Antibody:** The phrase monoclonal antibody in its various grammatical forms refers to a population of antibody molecules that contains only one species of antibody combining site capable of immunoreacting with a particular antigen.

30 **Multimeric:** A polypeptide molecule comprising more than one polypeptide. A multimer may be dimeric and contain two polypeptides and a multimer may be trimeric and contain three polypeptides. Multimers may be homomeric and contain two or more identical polypeptides or a multimer may be heteromeric and contain two or more nonidentical polypeptides.

35 **Non-acylated ghrelin-like compound:** a ghrelin like-compound as defined herein, which does not contain an acyl group attached to any of its constituent amino acids.

P 800 DK01

9

Polyclonal antibody: Polyclonal antibodies is a mixture of antibody molecules recognising a specific given antigen, hence polyclonal antibodies may recognise different epitopes within said antigen.

- 5 **Polypeptide:** The phrase polypeptide refers to a molecule comprising amino acid residues which do not contain linkages other than amide linkages between adjacent amino acid residues.

- 10 **Receptor:** A receptor is a molecule, such as a protein, glycoprotein and the like, that can specifically (non-randomly) bind to another molecule.

Secretagogue: A substance or chemical moiety capable of binding and activating the GHS 1a receptor.

- 15 **Specificity:** The term specificity refers to the number of potential antigen binding sites which immunoreact with (specifically bind to) a given polypeptide. The polypeptide may be a single polypeptide or may be two or more polypeptides joined by disulfide bonding.

- 20 **Surfactant molecule:** Molecule comprising a hydrophobic part and a hydrophilic part, i.e. molecule capable of being present in the interphase between a lipophilic phase and a hydrophilic phase.

Secretagogues

- 25 A growth hormone secretagogue according to the invention is used in its normal meaning, i.e. a substance capable of stimulating growth hormone release. In the present context, a secretagogue is defined by its ability of binding GHS-R 1a, and more preferably activating the receptor.

- 30 A secretagogue according to the invention is preferably selected from the group of:
L-692-429, L-692-585 (Benzolactam compounds)
MK677 (Spiroindaner)
G-7203, G-7039, G-7502 (Isonippecotic acid peptidomimetic)
35 NN703, Ipamorelin

P 800 DK01

10

In particular the secretagogue is a ghrelin-like compound, including 28 aa human ghrelin.

5 **Subcutaneous administration**

It is important to note that ghrelin receptors are found in a number of places in the organism besides on the GH producing cells and in the hypothalamic centers for appetite etc. control. In the CNS these receptors are tuned to receiving signals from local ghrelin containing neurons. Peripherally secreted or artificially administered ghrelin might not reach such sites due to the blood brain barrier, however currently available so-called GH secretagogues, which are small organic compounds such as MK-0677, will pass the blood brain barrier and also reach these sites – and consequently have the danger of causing unwanted side effects. Thus such compounds which do have the advantage of being for example orally active will not be optimal for mimicking the natural pre-meal, appetite inducing surge of ghrelin, since they will reach basically all ghrelin receptors in the body. In contrast, by using the natural peptide, ghrelin itself or homologues thereof, and administering it peripherally – as in the present invention – it is ensured that only the relevant, appetite regulating ghrelin receptors are reached and stimulated.

- 20 Any parenteral administration form that will ensure that the ghrelin receptors which normally are the target for peripherally produced ghrelin in the premeal situation will be exposed to sufficient levels of the bioactive form of ghrelin to ensure robust and appropriate appetite stimulation without causing desensitization of the system may be part of the present invention. However, taken into consideration that the individuals to be treated possibly will have to receive treatment for a longer period, such as weeks or months, it is preferred that the administration form is well suited herefor.
- 25 Accordingly, it is preferred that the ghrelin-like compound according to the invention is administered subcutaneously in an amount sufficient to allow sufficient levels of the bioactive form of ghrelin, i.e. the acylated form, to reach the receptors in time, such as prior to the forthcoming meal.

P 600 DK01

11

The present invention preferably deals with methods for administering ghrelin in a way which mimics the physiologically pre-meal situation as closely as possible yet providing patients in need of increased food intake, for example fragile elderly, post 5 operative patients, patients with lost appetite as part of cachexia for example precipitated by cancer, cardiac disease etc. with a sufficient extra stimulatory input to their appetite regulating ghrelin receptors, which normally are reached by ghrelin in the pre-meal situation.

Bolus administration

10

Furthermore, from a molecular pharmacological point-of-view it is important to note that it has been found that the ghrelin receptor normally is exposed to short-lived surges in the concentrations of the natural agonist ligand, ghrelin. The GHS-R 1a receptor belongs to the class of receptors, so-called G protein coupled receptors or 15 TM receptors, which upon continued exposure to an agonist will be desensitised, internalized and down-regulated. These mechanisms, which are inherent to the overall signal transduction system, involve processes such as receptor phosphorylation (which in itself decreases the affinity of the receptor for the agonist) binding of inhibitory proteins such as arrestin (which sterically block the binding of signal transduction molecules such as G proteins). Other part of the agonist mediated desensitization process is receptor internalization (i.e. physical removal of the receptor from the cell surface where it could bind the agonist) as well as receptor down regulation. (i.e. decreased production / expression of the receptor). Receptor internalization could after short-lived exposure of the receptor to agonist be followed by a re-sensitization process, where the receptor is dephosphorylated and recycled to the cell surface to be used again. Without being bound by theory, it is believed that, upon prolonged stimulation, which would occur for example during a long-lasting continuous infusion of the agonist, the receptor down-regulation process ensures that the target cell is adjusted in its signal transduction system etc. to this situation.

20

25 The present invention provides a procedure for an optimal administration of ghrelin to patients in order to obtain a maximal response and avoid for example desensitization mechanisms.

30

P 800 DK01

12

Accordingly, the present invention relates in one aspect to administration of the ghrelin-like compound in boluses, preferably a bolus prior to each main meal. It has been found, in contrary to the prolonged administration processes in the prior art, that a bolus administration leads to not only stimulation of appetite, but also to stimulation of feed intake and more important to stimulation of weight gain.

5

Without being bound by theory, it is believed that premeal subcutaneous injection, intravenous injection or short-term infusions of appropriate doses of ghrelin will ensure that a robust stimulation of appetite inducing ghrelin receptors will be obtained with minimal constraint to the mobility etc. of the patient. Thus for example patients with hip fractures can in the post operative situation be treated in the premeal period and if required during the meal as such, but will be free to move around and participate in the important post operative physiotherapeutic regimens.

10

15 Ghrelin-like compound

A ghrelin-like compound according to the invention described herein is a compound comprising a structure defined by formula I

20

$Z^1 - (X^1)_m - (X^2) - (X^3)_n - Z^2$, wherein

Z^1 is an optionally present protecting group

26

each X^1 is independently selected from an amino acid, wherein said amino acid is selected from naturally occurring and synthetic amino acids,

X^2 is any amino acid selected from naturally occurring and synthetic occurring amino acids, said amino acid being modified with a bulky hydrophobic group, preferably an acyl group, or a fatty acid,

30

each X^3 is independently selected from an amino acid, wherein said amino acid is selected from naturally occurring and synthetic amino acids,

35

wherein one or more of X^1 and X^3 optionally may be modified by a bulky hydrophobic group, preferably an acyl group, or a fatty acid,

P 800 DK01

13

Z^2 is an optionally present protecting group.

m is an integer in the range of from 1-10

5

n is 0 or an integer in the range of from 1-35.

Accordingly, the term "ghrelin-like compound" includes the naturally occurring 28 aa human ghrelin, the amino acid of which is shown in SEQ ID NO: 1, as well as the 10 naturally occurring 27 aa human ghrelin, the amino acid of which is shown in SEQ ID NO: 2. Thus, the present invention relates to the use of ghrelin or a peptide homologous thereto. Ghrelin is described by Kojima in Nature (1999), vol. 402, 656-660.

15 The present invention includes diastereomers as well as their racemic and resolved enantiomerically pure forms. Ghrelin-like compounds can contain D-amino acids, L-amino acids, alpha-amino acid, beta-amino acid, gamma-amino acid, natural amino acid and synthetic amino acid or the like or a combination thereof. Preferably, amino acids present in a ghrelin-like compound are the L-enantiomer.

20

The ghrelin-like compound comprises an amino acid modified with a bulky hydrophobic group. The number of amino acids N-terminally to the modified amino acid is preferably within the range of from 1-9. Accordingly, m is preferably an integer in the range of from 1-9, such as of from 1-8, such as of from 1-7, such as of from 1-6, 25 such as of from 1-5, such as of from 1-4, such as of from 1-3, such as of from 1-2, such as 2.

It is more preferred that the number of amino acids N-terminally to the modified amino acid is low, such as of from 1-3, such as of from 1-2. Most preferably 2 30 amino acids are positioned N-terminal to the modified amino acid.

In a preferred embodiment $(X^1)_m$ has a Gly residue in the N-terminal part of the sequence. Accordingly, in preferred embodiment $(X^1)_m$ is selected from the sequences:

P 800 DK01

14

Gly, Gly-Ser, Gly-Cys, Gly-Lys, Gly-Asp, Gly-Glu, Gly-Arg, Gly-His, Gly-Asn, Gly-Gln, Gly-Thr, and Gly-Tyr.

More preferably $(X^1)_m$ is selected from , Gly-Ser, and Gly-Cys, most preferably from
5 Gly-Ser.

In another words, in a preferred embodiment the ghrelin-like compound is selected
from a compound of

10 formula II $Z^1 - \text{Gly} - (X^1)_{m-1} - (X^2) - (X^3)_n - Z^2$,

formula III $Z^1 - \text{Gly} - \text{Ser} - (X^2) - (X^3)_n - Z^2$, and

formula IV $Z^1 - \text{Gly} - (X^2) - (X^3)_n - Z^2$.

15 And more preferably the ghrelin-like compound has formula III.

As described above, X^2 may be any amino acid modified with a bulky hydrophobic group. In particular X^2 is selected from the group of modified Ser, Cys, Asp, Lys, Trp, Phe, Ile, and Leu. More preferably X^2 is selected from the group of modified Ser, modified Cys and modified Lys, and most preferably X^2 is modified Ser.

Furthermore, $(X^1)_m - (X^2)$ is preferably Gly-Xaa-Ser*, or Gly-Xaa-Cys*, wherein Xaa is any amino acid, more preferably $(X^1)_m - (X^2)$ is Gly-Ser-Ser*, or Gly-Ser-Cys*,
25 wherein * indicates that the amino acid residue is modified with a bulky hydrophobic group.

30 $(X^3)_n$, preferably comprises a sequences which is a fragment of ghrelin, or a variant of a fragment of ghrelin, such as human ghrelin. Accordingly, $(X^3)_n$ preferably comprises a sequence selected from one or more of the sequences shown below:

Phe Leu Ser Pro Glu His Gln

Phe Leu Ser Pro Glu His

Phe Leu Ser Pro Glu

35 Phe Leu Ser Pro

P 800 DK01

15

Phe Leu Ser

Phe Leu

Phe

5 In a preferred embodiment the length of the ghrelin-like compound is substantially similar to the length of human ghrelin, i.e. 27 or 28 amino acids. Accordingly, n is preferably an integer in the range of from 1-25, such as of from 1-24, such as from 1-15, such as of from 1-10, or such as of from 10-25, such as of from 10-24, such as of from 15-25, such as of from 15-24.

10 $(X^3)_n$ may be selected from any fragment of ghrelin, such as human ghrelin, and accordingly, $(X^3)_n$ may be selected from one or more of the sequences shown below or a homologue thereof:

15 Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala Lys Leu Gln Pro Arg
Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala Lys Leu Gln Pro
Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala Lys Leu Gln
20 Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala Lys Leu
Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala Lys
25 Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala
Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro
Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys
30 Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys
Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser
Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu
Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys
Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg
35 Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln

P 800 DK01

16

Phe Leu Ser Pro Glu His Gln Arg Val Gln
 Phe Leu Ser Pro Glu His Gln Arg Val
 Phe Leu Ser Pro Glu His Gln Arg
 Phe Leu Ser Pro Glu His Gln
 5 Phe Leu Ser Pro Glu His
 Phe Leu Ser Pro Glu
 Phe Leu Ser Pro
 Phe Leu Ser
 Phe Leu
 10 Phe

Or selected from

Phe Leu Ser Pro Glu His Gln Lys Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
 15 Ala Lys Leu Gln Pro Arg
 Phe Leu Ser Pro Glu His Gln Lys Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
 Ala Lys Leu Gln Pro
 Phe Leu Ser Pro Glu His Gln Lys Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
 Ala Lys Leu Gln
 20 Phe Leu Ser Pro Glu His Gln Lys Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
 Ala Lys Leu
 Phe Leu Ser Pro Glu His Gln Lys Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
 Ala Lys
 Phe Leu Ser Pro Glu His Gln Lys Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
 25 Ala
 Phe Leu Ser Pro Glu His Gln Lys Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
 Phe Leu Ser Pro Glu His Gln Lys Val Gln Gln Arg Lys Glu Ser Lys Lys Pro
 Phe Leu Ser Pro Glu His Gln Lys Val Gln Gln Arg Lys Glu Ser Lys Lys
 Phe Leu Ser Pro Glu His Gln Lys Val Gln Gln Arg Lys Glu Ser Lys
 30 Phe Leu Ser Pro Glu His Gln Lys Val Gln Gln Arg Lys Glu Ser
 Phe Leu Ser Pro Glu His Gln Lys Val Gln Gln Arg Lys Glu
 Phe Leu Ser Pro Glu His Gln Lys Val Gln Gln Arg Lys
 Phe Leu Ser Pro Glu His Gln Lys Val Gln Gln Arg
 Phe Leu Ser Pro Glu His Gln Lys Val Gln Gln
 35 Phe Leu Ser Pro Glu His Gln Lys Val Gln

P 800 DK01

17

Phe Leu Ser Pro Glu His Gin Lys Val

Phe Leu Ser Pro Glu His Gin Lys

Or selected from

5

Phe Leu Ser Pro Glu His Gin Arg Ala Gin Gin Arg Lys Glu Ser Lys Lys Pro Pro

Ala Lys Leu Gin Pro Arg

Phe Leu Ser Pro Glu His Gin Arg Ala Gin Gin Arg Lys Glu Ser Lys Lys Pro Pro

Ala Lys Leu Gin Pro

10

Phe Leu Ser Pro Glu His Gin Arg Ala Gin Gin Arg Lys Glu Ser Lys Lys Pro Pro

Ala Lys Leu Gin

Phe Leu Ser Pro Glu His Gin Arg Ala Gin Gin Arg Lys Glu Ser Lys Lys Pro Pro

Ala Lys Leu

Phe Leu Ser Pro Glu His Gin Arg Ala Gin Gin Arg Lys Glu Ser Lys Lys Pro Pro

15

Ala Lys

Phe Leu Ser Pro Glu His Gin Arg Ala Gin Gin Arg Lys Glu Ser Lys Lys Pro Pro

Ala

Phe Leu Ser Pro Glu His Gin Arg Ala Gin Gin Arg Lys Glu Ser Lys Lys Pro Pro

Phe Leu Ser Pro Glu His Gin Arg Ala Gin Gin Arg Lys Glu Ser Lys Lys Pro

20

Phe Leu Ser Pro Glu His Gin Arg Ala Gin Gin Arg Lys Glu Ser Lys Lys

Phe Leu Ser Pro Glu His Gin Arg Ala Gin Gin Arg Lys Glu Ser Lys

Phe Leu Ser Pro Glu His Gin Arg Ala Gin Gin Arg Lys Glu Ser

Phe Leu Ser Pro Glu His Gin Arg Ala Gin Gin Arg Lys Glu

Phe Leu Ser Pro Glu His Gin Arg Ala Gin Gin Arg Lys

25

Phe Leu Ser Pro Glu His Gin Arg Ala Gin Gin Arg

Phe Leu Ser Pro Glu His Gin Arg Ala Gin Gin

Phe Leu Ser Pro Glu His Gin Arg Ala Gin

Phe Leu Ser Pro Glu His Gin Arg Ala

30

Or selected from

Phe Leu Ser Pro Glu His Gin Lys Ala Gin Gin Arg Lys Glu Ser Lys Lys Pro Pro

Ala Lys Leu Gin Pro Arg

Phe Leu Ser Pro Glu His Gin Lys Ala Gin Gin Arg Lys Glu Ser Lys Lys Pro Pro

35

Ala Lys Leu Gin Pro

P 800 DK01

18

Phe Leu Ser Pro Glu His Gln Lys Ala Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
 Ala Lys Leu Gln
 Phe Leu Ser Pro Glu His Gln Lys Ala Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
 Ala Lys Leu
 5 Phe Leu Ser Pro Glu His Gln Lys Ala Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
 Ala Lys
 Phe Leu Ser Pro Glu His Gln Lys Ala Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
 Ala
 Phe Leu Ser Pro Glu His Gln Lys Ala Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
 10 Phe Leu Ser Pro Glu His Gln Lys Ala Gln Gln Arg Lys Glu Ser Lys Lys Pro
 Phe Leu Ser Pro Glu His Gln Lys Ala Gln Gln Arg Lys Glu Ser Lys Lys
 Phe Leu Ser Pro Glu His Gln Lys Ala Gln Gln Arg Lys Glu Ser Lys
 Phe Leu Ser Pro Glu His Gln Lys Ala Gln Gln Arg Lys Glu Ser Lys
 Phe Leu Ser Pro Glu His Gln Lys Ala Gln Gln Arg Lys Glu Ser
 15 Phe Leu Ser Pro Glu His Gln Lys Ala Gln Gln Arg Lys Glu
 Phe Leu Ser Pro Glu His Gln Lys Ala Gln Gln Arg
 Phe Leu Ser Pro Glu His Gln Lys Ala Gln Gln
 Phe Leu Ser Pro Glu His Gln Lys Ala Gln
 Phe Leu Ser Pro Glu His Gln Lys Ala
 20 In another embodiment (X^3)_n preferably comprises or consists of a sequence se-
 lected from the sequences

25 Phe Leu Ser Pro Glu His Gln
 Phe Leu Ser Pro Glu His
 Phe Leu Ser Pro Glu
 Phe Leu Ser Pro
 Phe Leu Ser
 Phe Leu
 30 Phe

Functionality

35 The ghrelin-like compound described herein are active at the GHS receptor. The
 compounds can bind to the receptor, and preferably, stimulate receptor activity.

P 800 DK01

19

GHS receptor activity can be measured using different techniques such as detecting a change in the intracellular conformation of the GHS receptor, in the G-protein coupled activities, and/or in the intracellular messengers.

5

One simple measure of the ability of a ghrelin like compound to activate the ghrelin receptor is to measure its EC₅₀, i.e. the dose at which the compound is able to activates the signalling of the receptor to half of the maximal effect of the compound. The ghrelin receptor can either be expressed endogenously on primary cells cultures, for example pituitary cells, or heterologously expressed on cells transfected with the ghrelin receptor. Whole cell assays or assays using membranes prepared from either of these cell types can be used depending on the type of assay.

10

15

As the ghrelin receptor is generally believed to be primarily coupled to the Gq signalling pathway, any suitable assay which monitor activity in the Gq/G11 signalling pathway can be used, for example:

20

1) an assay measuring the activation of Gq / G11 performed for example by measurement of GTP_gS binding combined with, e.g., anti-Gα-q or -11 antibody precipitation in order to increase the signal to noise ratio. This assay may also detect coupling to other G-proteins than Gq/11.

25

2) An assay which measure the activity of phospholipase C (PLC) one of the first down-stream effector molecules in the pathway, for example by measuring the accumulation of inositol phosphate which is one of the products of PLC.

3) More down stream in the signalling cascade is the mobilization of calcium from the intracellular stores

30

4) Further more down stream signalling molecules such as the activity of different kinds of MAP kinases (p38, jun, ect.), NF-κ-B translocation and CRE driven gene transcription may also be measured.

35 Alternatively binding of fluorescently tagged arrestin to the activated ghrelin receptor may also be used.

P 800 DK01

20

In one embodiment the binding of a compound to the receptor GHS-R 1A can be measured by the use of the assay described herein above.

5 A ghrelin-like compound according to the invention preferably has at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%, functional activity relative to 28 aa human ghrelin as determined using the assay described herein above, and/or an EC50 greater than about 1,000, greater than about 100, or greater than about 50, or greater than about 10. Greater refers to potency and thus indicates a lesser amount is needed to achieve binding inhibition.

10 In one embodiment of the invention the compound has a potency (EC50) on the GHS-R 1A of less than 500 nM. In another embodiment the compound has a potency (EC50) on the GHS-R 1A of less than 100 nM, such as less than 80 nM, for example less than 60 nM, such as less than 40 nM, for example less than 20 nM, such as less than 10 nM, for example less than 5 nM, such as less than 1 nM, for example less than 0.5 nM, such as less than 0.1 nM, for example less than 0.05 nM, such as less than 0.01 nM.

15 In a further embodiment the dissociation constant (Kd) of the compound is less than 500 nM. In a still further embodiment the dissociation constant (Kd) of the ligand is less than 100 nM, such as less than 80 nM, for example less than 60 nM, such as less than 40 nM, for example less than 20 nM, such as less than 10 nM, for example less than 5 nM, such as less than 1 nM, for example less than 0.5 nM, such as less than 0.1 nM, for example less than 0.05 nM, such as less than 0.01 nM.

20 Binding assays can be performed using recombinantly produced GHS receptor polypeptides present in different environments. Such environments include, for example, cell extracts and purified cell extracts containing the GHS receptor polypeptide expressed from recombinant nucleic acid or naturally occurring nucleic acid; and also include, for example, the use of a purified GHS receptor polypeptide produced by recombinant means or from naturally occurring nucleic acid which is introduced into a different environment.

P 800 DK01

21

Using a recombinantly expressed GHS receptor offers several advantages such as the ability to express the receptor in a defined cell system so that a response to a compound at the GHS receptor can more readily be differentiated from responses at other receptors. For example, the GHS receptor can be expressed in a cell line such as HEK 293, COS 7, and CHO not normally expressing the receptor by an expression vector, wherein the same cell line without the expression vector can act as a control.

Identity and homology

The term "identity" or "homology" shall be construed to mean the percentage of amino acid residues in the candidate sequence that are identical with the residue of a corresponding sequence to which it is compared, after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent identity for the entire sequence, and not considering any conservative substitutions as part of the sequence identity. Neither N- or C-terminal extensions nor insertions shall be construed as reducing identity or homology. Methods and computer programs for the alignment are well known in the art. Sequence identity may be measured using sequence analysis software (e.g., Sequence Analysis Software Package, Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Ave., Madison, Wis. 53705). This software matches similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications.

A homologue of one or more of the sequences specified herein may vary in one or more amino acids as compared to the sequences defined, but is capable of performing the same function, i.e. a homologue may be envisaged as a functional equivalent of a predetermined sequence.

As described above a homologue of any of the predetermined sequences herein may be defined as:

- i) homologues comprising an amino acid sequence capable of being recognised by an antibody, said antibody also recognising the 28 aa human ghrelin, preferably the acylated 28 aa human ghrelin, and/or

35

P 800 DK01

22

- ii) homologues comprising an amino acid sequence capable of binding selectively to GHS-R 1a, and/or
- iii) homologues having a substantially similar or higher binding affinity to GHS-R 1a than the 28 aa human ghrelin, preferably the acylated 28 aa human ghrelin.

5 In the above examples, the 28 aa human ghrelin has the sequence shown in SEQ ID NO: 1, and when acylated is acylated in position 3.

10 The antibodies used herein may be antibodies binding the N-terminal part of ghrelin or the C-terminal part of ghrelin, preferably the N-terminal part of ghrelin. The antibodies may be antibodies as described in Ariyasu et al. "Delayed short-term secretory regulation of ghrelin in obese animals: Evidenced by a specific RIA for the active form of ghrelin, Endocrinology 143(9):3341-3350, 2002.

15

20 Examples of homologues comprises one or more conservative amino acid substitutions including one or more conservative amino acid substitutions within the same group of predetermined amino acids, or a plurality of conservative amino acid substitutions, wherein each conservative substitution is generated by substitution within a different group of predetermined amino acids.

25 Homologues may thus comprise conservative substitutions independently of one another, wherein at least one glycine (Gly) of said homologue is substituted with an amino acid selected from the group of amino acids consisting of Ala, Val, Leu, and Ile, and independently thereof, homologues, wherein at least one of said alanines (Ala) of said homologue thereof is substituted with an amino acid selected from the group of amino acids consisting of Gly, Val, Leu, and Ile, and independently thereof, homologues, wherein at least one valine (Val) of said homologue thereof is substituted with an amino acid selected from the group of amino acids consisting of Gly, Ala, Leu, and Ile, and independently thereof, homologues thereof, wherein at least one of said leucines (Leu) of said homologue thereof is substituted with an amino acid selected from the group of amino acids consisting of Gly, Ala, Val, and Ile, and independently thereof, homologues thereof, wherein at least one isoleucine (Ile) of said homologues thereof is substituted with an amino acid selected from the group

30

35

P 800 DK01

23

- of amino acids consisting of Gly, Ala, Val and Leu, and independently thereof, homologues thereof wherein at least one of said aspartic acids (Asp) of said homologue thereof is substituted with an amino acid selected from the group of amino acids consisting of Glu, Asn, and Gln; and independently thereof, homologues thereof, wherein at least one of said phenylalanines (Phe) of said homologues thereof is substituted with an amino acid selected from the group of amino acids consisting of Tyr, Trp, His, Pro, and preferably selected from the group of amino acids consisting of Tyr and Trp, and independently thereof, homologues thereof, wherein at least one of said tyrosines (Tyr) of said homologues thereof is substituted with an amino acid selected from the group of amino acids consisting of Phe, Trp, His, Pro, preferably an amino acid selected from the group of amino acids consisting of Phe and Trp, and independently thereof, homologues thereof, wherein at least one of said arginines (Arg) of said fragment is substituted with an amino acid selected from the group of amino acids consisting of Lys and His, and independently thereof, homologues thereof, wherein at least one lysine (Lys) of said homologues thereof is substituted with an amino acid selected from the group of amino acids consisting of Arg and His, and independently thereof, homologues thereof, wherein at least one of said asparagines (Asn) of said homologues thereof is substituted with an amino acid selected from the group of amino acids consisting of Asp, Glu, and Gln, and independently thereof, homologues thereof, wherein at least one glutamine (Gln) of said homologues thereof is substituted with an amino acid selected from the group of amino acids consisting of Asp, Glu, and Asn, and independently thereof, homologues thereof, wherein at least one proline (Pro) of said homologues thereof is substituted with an amino acid selected from the group of amino acids consisting of Phe, Tyr, Trp, and His, and independently thereof, homologues thereof, wherein at least one of said cysteines (Cys) of said homologues thereof is substituted with an amino acid selected from the group of amino acids consisting of Asp, Glu, Lys, Arg, His, Asn, Gln, Ser, Thr, and Tyr.
- Conservative substitutions may be introduced in any position of a preferred predetermined sequence. It may however also be desirable to introduce non-conservative substitutions, particularly, but not limited to, a non-conservative substitution in any one or more positions.

P 800 DK01

24

A non-conservative substitution leading to the formation of a functionally equivalent homologue of the sequences herein would for example i) differ substantially in polarity, for example a residue with a non-polar side chain (Ala, Leu, Pro, Trp, Val, Ile, Leu, Phe or Met) substituted for a residue with a polar side chain such as Gly, Ser,

5 Thr, Cys, Tyr, Asn, or Gln or a charged amino acid such as Asp, Glu, Arg, or Lys, or substituting a charged or a polar residue for a non-polar one; and/or ii) differ substantially in its effect on polypeptide backbone orientation such as substitution of or for Pro or Gly by another residue; and/or iii) differ substantially in electric charge, for example substitution of a negatively charged residue such as Glu or Asp for a positively charged residue such as Lys, His or Arg (and vice versa); and/or iv) differ substantially in steric bulk, for example substitution of a bulky residue such as His, Trp, Phe or Tyr for one having a minor side chain, e.g. Ala, Gly or Ser (and vice versa).

15 Substitution of amino acids may in one embodiment be made based upon their hydrophobicity and hydrophilicity values and the relative similarity of the amino acid side-chain substituents, including charge, size, and the like. Exemplary amino acid substitutions which take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

In a preferred embodiment the binding domain comprises a homologue having an amino acid sequence at least 60 % homologous to SEQ ID NO 1.

25 More preferably the homology is at least 65 %, such as at least 70 % homologous, such as at least 75 % homologous, such as at least 80 % homologous, such as at least 85 % homologous, such as at least 90 % homologous, such as at least 95 % homologous, such as at least 98 % homologous to SEQ ID NO 1.

30 In a more preferred embodiment the percentages mentioned above relates to the identity of the sequence of a homologue as compared to SEQ ID NO 1.

35 Homologues to SEQ ID NO: 1 may be 27 aa human ghrelin SEQ ID NO: 2, rat ghrelin SEQ ID NO: 3; Other homologues are the variants described in EP 1197496 (Kangawa) incorporated herein by reference.

P 800 DK01

25

Bulky hydrophobic group

- The bulky hydrophobic group of the ghrelin-like compound according to the invention is any bulky hydrophobic group capable of providing the des-acylated 28 aa human ghrelin with binding affinity to GHS-R 1a when the Ser residue in position 3 is modified with the bulky hydrophobic group.
- When the amino acid being modified contains e.g. - OH, -SH, -NH or -NH₂ as a substituent group in a side chain thereof, a group formed by acylating such a substituent group is preferred. The mode of linkage may thus be selected from the group consisting of ester, ether, thioester, thioether, amide and carbamide.
- For example, if the modified amino acid is serine, threonine, tyrosine or oxyproline, the amino acid has a hydroxyl group in the side chain. If the modified amino acid is cysteine, the amino acid has a mercapto group in the side chain. If the modified amino acid is lysine, arginine, histidine, tryptophan, proline oxyproline, it has an amino group or imino group in the side chain.
- The hydroxyl group, mercapto group, amino group and imino group described above may thus have been chemically modified. That is, the hydroxyl group or mercapto group may be etherized, esterified, thioetherified or thioesterified. The imino group may have been iminoetherified, iminothioetherified or alkylated. The amino group may have been amidated, thioamidated or carbamidated.
- Further, the mercapto group may have been disulfidated, the imino group may have been amidated or thioamidated, and the amino group may have been alkylated or thiocarbamidated.
- In a preferred embodiment the modified amino acid is Ser coupled through an ester linkage to the hydrophobic group.
- The hydrophobic group may be any group with a saturated or unsaturated alkyl or acyl group containing one or more carbon atoms. In one embodiment the bulky hydrophobic group is an acyl group, including groups formed by removing a hydroxyl.

P 800 DK01

26

group from an organic carboxylic acid, organic sulfonic acid or organic phosphoric acid. The organic carboxylic acid includes e.g. fatty acids, and the number of carbon atoms thereof is preferably 1 to 35. In the organic sulfonic acid or organic phosphoric acid, the number of carbon atoms thereof is preferably 1 to 35.

5

Accordingly, the acyl group is preferably selected from a C1-C35 acyl group, such as a C1 – C20 acyl group, such as a C1 – C15 acyl group, such as a C6 – C15 acyl group, such as a C6 – C12 acyl group, such as a C8 – C12 acyl group.

10

More preferably the acyl group is selected from the group of C7 acyl group, C8 acyl group, C9 acyl group, C10 acyl group, C11 acyl group, and C12 acyl group. Such acyl group may be formed from octanoic acid (preferably caprylic acid), decanoic acid (preferably capric acid), or dodecanoic acid (preferably lauric acid), as well as monoene or polyene fatty acids thereof.

15

In one embodiment the acyl group is selected from the group of C8 acyl group, and C10 acyl group. Such acyl groups may be formed from octanoic acid (preferably caprylic acid), or decanoic acid (preferably capric acid).

20

In another embodiment the acyl group is selected from the group of C7 acyl group, C9 acyl group, and C11 acyl group, such as from the group of C9 acyl group and C11 acyl group.

25

Furthermore, the modified amino acid may be any amino acid wherein a group is modified as described in EP 1 197 496 (Kangawa), which is hereby incorporated by reference.

Protecting group

30

The ghrelin-like compound according to the invention may comprise a protecting group at the N-terminus or the C-terminus or at both.

A protecting group covalently joined to the N-terminal amino group reduces the reactivity of the amino terminus under in vivo conditions. Amino protecting groups in-

P 800 DK01

27

clude - C1-10 alkyl, -C1-10 substituted alkyl, -C2-10 alkenyl, -C2-10 substituted alkenyl, aryl, -C1-6 alkyl aryl, -C(O)- (CH₂) 1-6-COOH, -C(O)-C1-6 alkyl, -C(O)-aryl, -C (O)-O-C1-6 alkyl, or-C (O)-O-aryl. Preferably, the amino terminus protecting group is acetyl, propyl, succinyl, benzyl, benzyloxycarbonyl or tbutyloxycarbonyl.

- 5 A protecting group covalently joined to the C-terminal carboxy group reduces the reactivity of the carboxy terminus under in vivo conditions. The carboxy terminus protecting group is preferably attached to the α-carbonyl group of the last amino acid. Carboxy terminus protecting groups include amide, methylamide, and ethylamide.
- 10

Conjugates

- 15 The ghrelin-like compound may also be administered in a form, wherein the ghrelin-like compound is conjugated to another entity.

- For example the compound may be a conjugate of ghrelin or a derivative or homologue thereof and another peptide, such as a peptide having effect on nociceptin receptor ORL1. In one embodiment the conjugate is a conjugate of ghrelin or a derivative or homologue thereof and Ac-RYY(RK)(W)RK-NH₂, where the brackets show allowable variation of amino acid residues. Examples peptides in the conjugate may also be found in US patent application 2003040472

Method for production

- 25 Ghrelin-like compounds can be produced using techniques well known in the art. For example, a polypeptide region of a ghrelin-like compound can be chemically or biochemically synthesized and modified. Techniques for chemical synthesis of polypeptides are well known in the art. (See e. g., Vincent in Peptide and Protein Drug Delivery, New York, N. Y., Dekker, 1990.) Examples of techniques for biochemical synthesis involving the introduction of a nucleic acid into a cell and expression of nucleic acids are provided in Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-1998, and Sambrook et al., in Molecular Cloning, A Laboratory Manual, 2 d Edition, Cold Spring Harbor Laboratory Press, 1989.
- 30

P 800 DK01

28

Pharmaceutical composition

- In one aspect the invention relates to a pharmaceutical composition comprising a
5 ghrelin-like compound as defined herein, wherein the bulky hydrophobic group is an acyl group selected from the group of C7 acyl group, C9 acyl group, and C11 acyl group, such as from the group of C9 acyl group and C11 acyl group.
- In another embodiment the invention relates to a pharmaceutical composition comprising a mixture of at least two different ghrelin-like compounds, such as a mixture of a ghrelin-like compound being acylated with a C8 acyl and a ghrelin-like compound being acylated with a C10 acyl. Without being bound by theory it is believed that such a mixture will have a longer half-life in plasma, or will more closely resemble the natural situation.
10
- 15 In yet another embodiment, the pharmaceutical composition comprises acylated ghrelin-like compounds, optionally compounds having different acyl chain lengths preferably selected from the group of C7 acyl group, C9 acyl group, and C11 acyl group, such as from the group of C9 acyl group and C11 acyl group, further optionally in combination with a desacylated Ghrelin-like compound.
20
- In another aspect the invention relates to a pharmaceutical composition comprising any compound as defined above or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable carriers, vehicles and/or excipients said composition further comprising transport molecules. The transport molecules are primarily added in order to increase the half-life of the acylated compound, preventing premature des-acylation, since the des-acylated ghrelin is not active at the GHS-R 1a.
25
- 30 Transport molecules act by having incorporated into or anchored to it the compound according to the invention.
- Any suitable transport molecules known to the skilled person may be used. Examples of transport molecules may be liposomes, micelles, and/or microspheres.

P 800 DK01

29

A variety of methods are available for preparing liposomes, as described in, e.g., Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), U.S. Pat. Nos. 4, 235,871, 4,501,728 and 4,837,028, all of which are incorporated herein by reference. One method produces multilamellar vesicles of heterogeneous sizes. In this method, the vesicle-forming lipids are dissolved in a suitable organic solvent or solvent system and dried under vacuum or an inert gas to form a thin lipid film. If desired, the film may be redissolved in a suitable solvent, such as tertiary butanol, and then lyophilized to form a more homogeneous lipid mixture which is in a more easily hydrated powderlike form. This film is covered with an aqueous solution of the targeted drug and the targeting component and allowed to hydrate, typically over a 15-60 minute period with agitation. The size distribution of the resulting multilamellar vesicles can be shifted toward smaller sizes by hydrating the lipids under more vigorous agitation conditions or by adding solubilizing detergents such as deoxycholate. Additionally, the liposome suspension may include lipid-protective agents which protect lipids against free-radical and lipid-peroxidative damages on storage. Lipophilic free-radical quenchers, such as α -tocopherol and water-soluble iron-specific chelators, such as ferrioxamine, are preferred.

Micelles are formed by surfactants (molecules that contain a hydrophobic portion and one or more ionic or otherwise strongly hydrophilic groups) in aqueous solution. As the concentration of a solid surfactant increases, its monolayers adsorbed at the air/water or glass/water interfaces become so tightly packed that further occupancy requires excessive compression of the surfactant molecules already in the two monolayers. Further increments in the amount of dissolved surfactant beyond that concentration cause amounts equivalent to the new molecules to aggregate into micelles. This process begins at a characteristic concentration called "critical micelle concentration".

The shape of micelles formed in dilute surfactant solutions is approximately spherical. The polar head groups of the surfactant molecules are arranged in an outer spherical shell whereas their hydrocarbon chains are oriented toward the center, forming a spherical core for the micelle. The hydrocarbon chains are randomly coiled and entangled and the micellar interior has a nonpolar, liquid-like character. In the micelles of polyoxyethylated nonionic detergents, the polyoxyethylene moieties are oriented outward and permeated by water. This

P 800 DK01

30

arrangement is energetically favorable since the hydrophilic head groups are in contact with water and the hydrocarbon moieties are removed from the aqueous medium and partly shielded from contact with water by the polar head groups. The hydrocarbon tails of the surfactant molecules, located in the interior of the micelle,
5 interact with one another by weak van der Waals forces.

The size of a micelle or its aggregation number is governed largely by geometric factors. The radius of the hydrocarbon core cannot exceed the length of the extended hydrocarbon chain of the surfactant molecule. Therefore, increasing the
10 chain length or ascending homologous series increases the aggregation number of spherical micelles. If the surfactant concentration is increased beyond a few percent and if electrolytes are added (in the case of ionic surfactants) or the temperature is raised (in the case of nonionic surfactants), the micelles increase in size. Under these conditions, the micelles are too large to remain spherical and become
15 ellipsoidal, cylindrical or finally lamellar in shape.

Common surfactants well known to one of skill in the art can be used in the micelles of the present invention. Suitable surfactants include sodium laurate, sodium oleate, sodium lauryl sulfate, octaoxyethylene glycol monododecyl ether, octoxynol
20 9 and PLURONIC F-127 (Wyandotte Chemicals Corp.). Preferred surfactants are nonionic polyoxyethylene and polyoxypropylene detergents compatible with IV injection such as, TWEEN-80, PLURONIC F-68, n-octyl-.beta.-D-glucopyranoside, and the like. In addition, phospholipids, such as those described for use in the production of liposomes, may also be used for micelle formation.
25

Administration

Suitable dosing regimens are preferably determined taking into account factors well known in the art including type of subject being dosed; age, weight, sex and medical
30 condition of the subject; the route of administration; the renal and hepatic function of the subject; the desired effect; and the particular compound employed.

Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's

P 800 DK01

31

availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.

As described above, in one aspect of the invention, the ghrelin-like compound is
5 administered subcutaneously.

In another aspect the ghrelin-like compound is administered as a premeal bolus, wherein the administration form may be any suitable parenteral form.

10 In a preferred embodiment the ghrelin-like compound is administered subcutaneously in a premeal bolus.

The ghrelin-like compound can also be administered during a meal as a bolus. The mode of administration during a meal includes subcutaneous administration, such
15 as a subcutaneously administered bolus.

20 Pharmaceutical compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions, as well as sterile powders to be reconstituted in sterile injectable solutions or disper-
sions prior to use.

Other suitable administration forms include suppositories, sprays, ointments, creams, gels, inhalants, dermal patches, implants, pills, tablets, lozenges and capsules.

25 A typical dosage of a compound employed according to the invention is in a concentration equivalent to from 10 ng to 10 mg ghrelin per kg bodyweight. The concentrations and amounts herein are given in equivalents of amount ghrelin, wherein
30 the ghrelin is the 28 aa human ghrelin. Equivalents may be tested a method as de-
scribed in Example 2.

In a preferred embodiment the medicament is administered in a concentration equivalent to from 0.1 µg to 1 mg ghrelin per kg bodyweight, such as from 0.5 µg to
0.5 mg ghrelin per kg bodyweight, such as from 1.0 µg to 0.1 mg ghrelin per kg

P 800 DK01

32

bodyweight, such as from 1.0 µg to 50 µg ghrelin per kg bodyweight, such as from 1.0 µg to 10 µg ghrelin per kg bodyweight.

As described above, the ghrelin-like compound is preferably administered as a bolus. Accordingly, in one embodiment the medicament is administered as a bolus prior to a meal, said bolus comprising an amount of the ghrelin-like compound or a salt thereof equivalent to from 0.3 µg to 600 mg ghrelin. More preferred the medicament is administered as a bolus prior to a meal, said bolus comprising an amount of the ghrelin-like compound or a salt thereof equivalent to from 2.0 µg to 10 mg ghrelin, such as from 5.0 µg to 100 mg ghrelin, such as from 10 µg to 50 mg ghrelin, such as from 10 µg to 5 mg ghrelin, such as from 10 µg to 1.0 mg ghrelin.

It should be noted that the normal ghrelin response which occurs before a meal is a short-lived surge in plasma concentrations of ghrelin and that due to the relative short half life of the peptide an i.v. injection of ghrelin will ensure that a similar short-lived peak on ghrelin concentrations can be obtained. The administration route must ensure that the non-degraded, bioactive form of the peptide will be the dominating form in the circulation, which will reach the ghrelin receptors and stimulate these. Thus, in order to obtain the maximum effect of the medicament it is preferably administered from one to three times daily, each administration being within 45 minutes of a meal, such as within 30 minutes of a meal, such as within 25 minutes of a meal, such as within 20 minutes of a meal, such as within 15 minutes of a meal, such as within 10 minutes of a meal, such as within 5 minutes of a meal. More preferred the medicament is administered prior to each main meal, such as administered three times daily.

Formulation

In a preferred aspect the present invention contemplates pharmaceutical compositions useful for practicing the therapeutic methods described herein. Pharmaceutical compositions of the present invention contain a physiologically tolerable carrier together with at least one species of ghrelin-like compound as described herein, dissolved or dispersed therein as an active ingredient. In a preferred embodiment, the pharmaceutical composition is not immunogenic when administered to a human

P 800 DK01

33

individual for therapeutic purposes, unless that purpose is to induce an immune response.

- In one aspect the invention relates to a pharmaceutical composition comprising at least one ghrelin-like compound as defined above. In a preferred embodiment the pharmaceutical composition comprises at least two different ghrelin-like compounds as defined above in order to increase the effect of the treatment. The difference may for example be compounds having different acylations as discussed above.
- As used herein, the terms "pharmaceutically acceptable", "physiologically tolerable" and grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to or upon a human without the production of undesirable physiological effects such as nausea, dizziness, gastric upset and the like.
- The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art. Typically such compositions are prepared as sterile injectables either as liquid solutions or suspensions, aqueous or non-aqueous, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared. The preparation can also be emulsified.
- The active ingredient can be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient.
- The pharmaceutical composition of the present invention can include pharmaceutically acceptable salts of the compounds therein. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide).

P 800 DK01

34

Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium salts and alkylated ammonium salts. Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydriodic,

- 5 · phosphoric, sulphuric and nitric acids and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanesulfonic, gluconic, citraconic, aspartic, stearic, palmitic, ethylenediaminetetraacetic (EDTA), p-aminobenzoic, glutamic, benzenesulfonic and ptoluenesulfonic acids and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutical acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference. Examples of metal salts include lithium, sodium, potassium and magnesium salts and the like.

- 10 · Examples of ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium and tetramethylammonium salts and the like.

- 15 · Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

- 20 · Also included within the scope of compounds or pharmaceutical acceptable acid addition salts thereof in the context of the present invention are any hydrates (hydrated forms) thereof.

- 25 · For parenteral administration, solutions of the present compounds in sterile aqueous solution, aqueous propylene glycol or sesame or peanut oil may be employed. Such aqueous solutions should be suitably buffered if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperi-

P 800 DK01

35

tonal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.

5 Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerin, vegetable oils such as cottonseed oil, organic esters such as ethyl oleate, and water-oil emulsions.

10 Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. Examples of solid carriers are lactose, terna alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid or lower alkyl ethers of cellulose. Examples of liquid carriers are syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene or water. Administered by nasal aerosol or inhalation formulations may be prepared, for example, as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, employing fluorocarbons, and/or employing other solubilizing or dispersing agents.

20 The pharmaceutical compositions formed by combining the compounds of the invention and the pharmaceutical acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration. The formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.

25 In a preferred embodiment of the invention the formulation comprises the ghrelin-like compound or a salt thereof as a lyophilisate and the formulation further comprises a solvent, said lyophilisate and said solvent being in separate compartments until administration.

30 In another embodiment the formulation is a solution of the ghrelin-like compound or a salt thereof.

In both embodiment the solvent may be any suitable solvents, such as described herein, and preferably the solvent is saline.

P 800 DK01

36

The invention also relates to a method for preparing a medicament or pharmaceutical composition comprising an compound of the invention, comprising admixing at least one ghrelin-like compound as defined above with a physiologically acceptable carrier.

5

In a still further aspect, the invention relates to a pharmaceutical composition comprising, as an active ingredient, a compound as defined above or a pharmaceutical acceptable salt thereof together with a pharmaceutical acceptable carrier.

10

Accordingly, the formulation may further include the transport molecules as described above.

Administration of ghrelin with further pharmacologically active substances
In a further aspect of the invention the present compounds may be administered in combination with further pharmacologically active substances, e. g. an antidiabetic agent or other pharmacologically active material, including other compounds for the treatment and/or prevention of insulin resistance and diseases wherein insulin resistance is the pathophysiological mechanism. The combination may be in the form of kit-in-part systems, wherein the combined active substances may be used for simultaneous, sequential or separate administration.

20

As an example of a further pharmacologically active substance, the ghrelin-like compounds according to the invention can be administered in combination with a pharmaceutically effective amount of a growth hormone, including hGH.

25

Therapy with rhGH has been reported to cause reduction in the size of 'buffalo hump', truncal fat and to increase the lean body mass in a small number of patients. However, fat loss and lipid abnormalities did not improve and blood glucose control worsened. Examples of syndromes treated with hGH include HIV, AIDS and cancer. Without being bound by theory, it is believed that treatment with ghrelin or a analog thereof would maintain and/or increase body fat in patients being treated with hGH, thereby effectively counteracting or at least reducing lipodystrophy caused by hGH.

30

Thus, in one preferred embodiment, the present invention relates to use of ghrelin or an analog thereof in combination with a growth hormone, preferably in individuals suffering from HIV or AIDS and/or cancer cachexia. Said treatment with ghrelin or

P 800 DK01

37

an analog thereof may be prior to, and/or during and/or after the individual is subjected to treatment with a growth hormone. Said growth hormone is preferably hGH.

5 Uses and combination treatments according to the invention can also involve administration of the ghrelin-like compound in combination with another pharmacologically active substance capable of treating or ameliorating lipodystrophy in an individual in need of such treatment. Preferred embodiments of other pharmacologically active substances that may be administered in combination with said ghrelin-like compound comprise:

10 1) Leptin: leptin has been shown to have a positive effect on the metabolic abnormalities associated with lipodystrophy. This treatment has proven to be beneficial both to those patients that suffer from a low plasma level of leptin and to those that have a normal level.

15 2) Peroxisome proliferator-activated receptor (PPAR-γ) agonists: PPAR-γ has in several studies been demonstrated to be important for adipocyte metabolism and metabolic syndrome and it is proposed that PPAR-γ agonists will decrease the symptoms of lipodystrophy.

20 3) Agonists of the renin-angiotensin system: it has been shown that treatment with HAART increases the activity of ACE in the T-cells, which means that agonists of the rennin-angiotensin system may improve HAART induced lipodystrophy.

25 4) Opioid receptor antagonists: opioid receptor antagonists, such as Naloxone and Naltrexone, have been shown to prolong the period of time from protease inhibitor treatment to development of the first symptoms of lipodystrophy.

30 Uses and combination treatments involving administration of the ghrelin-like compound according to the invention can also involve prophylaxis or treatment of lipodystrophy in combination with one or more of

35 a) prophylaxis and/or alleviation and/or treatment of a clinical depression, which combination treatment further comprises administering an antidepressant, a prodrug thereof, or a pharmaceutically acceptable salt of said antidepressant or said prodrug, and/or

P 800 DK01

38

- b) prophylaxis and/or alleviation and/or treatment of an emetic condition, including nausea and vomiting, which combination treatment further comprises administering an antiemetic agent, a prodrug thereof, or a pharmaceutically acceptable salt of said antiemetic agent or said prodrug, and/or
- 5 c) prophylaxis and/or alleviation and/or treatment of a psychotic condition, which combination treatment further comprises administering an antipsychotic agent, a prodrug thereof or a pharmaceutically acceptable salt of said antipsychotic agent or said prodrug, and/or
- 10 d) prophylaxis and/or alleviation and/or treatment of anxiety, which combination treatment further comprises administering an antianxiety agent, a prodrug thereof or a pharmaceutically acceptable salt of said antianxiety agent or said prodrug, and/or
- 15

Clinical Depression

- Clinical depression is characterized by a combination of symptoms that interfere with the ability to work, study, sleep, eat, and enjoy once pleasurable activities.
- 20 Symptoms include: persistent sad or anxious mood; feelings of hopelessness or pessimism; feelings of guilt, worthlessness or helplessness; loss of interest in pleasure activities; decreased energy; difficulty concentrating, remembering, or making decisions; sleep abnormalities (e.g. insomnia); appetite and/or weight loss; thoughts of death or suicide; restlessness; and irritability.
- 25 Depression is a common disorder, occurring in approximately 10 percent of the U.S. population. Major depression is a leading cause of disability in the U.S. and worldwide, and a leading cause of days lost from work. Many causes of clinical depression having roots in the anatomy of the human brain. Neurotransmitter activity, genetic predisposition, and environmental factors are believed to be involved in the development of depression.
- 30

- 35 Diagnosis of depression is complicated, requiring a physical examination to rule out certain medications or medical conditions and a psychological examination to thoroughly evaluate the symptoms and determine how severely the symptoms have

P 800 DK01

39

affected the life of the patient. Accordingly, depression is difficult to diagnose due to the variety of ways in which depression manifests itself:

- 5 In the above combination treatment, the antidepressant is preferably a norepinephrine reuptake Inhibitor (NERI), a selective serotonin reuptake inhibitor (SSRI), a monoamine oxidase inhibitor (MAO), a combined NERI/SSRI, or an atypical antidepressant; a prodrug of said antidepressant or a pharmaceutically acceptable salt of said antidepressant or said prodrug.
- 10 One preferred antidepressant is a selective serotonin reuptake inhibitor (SSRI), a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug. The SSRI is preferably citalopram, escitalopram, fexloxetine, fluoxetine, fluvoxamine, indalpine, indeloxazine, milnacipran, paroxetine, sertraline, sibutramine or zimeldine, a prodrug of said SSRI or a pharmaceutically acceptable salt of said SSRI or said prodrug. Of the above, citalopram and escitalopram, a prodrug or a pharmaceutically acceptable salt thereof, are preferred in certain embodiments of combination treatments according to the present invention.
- 15

Emesis, including nausea and vomiting

- 20 Emesis can be caused by a number of factors, including medication. Emesis can thus be an unavoidable side effect associated with many forms of medication. Preferred antiemetic agents according to the invention include meclizine hydrochloride, prochlorperazine, promethazine, trimethobenzamide hydrochloride and ondansetron
- 25 hydrochloride.

Clinical Psychotic Condition

- 30 There are few psychiatric disorders in which clinical manifestations and symptoms can be correlated with a demonstrable pathology. The majority of mental illnesses are evaluated by observing changes in key behaviors such as thinking, mood, or social behavior. These alterations are difficult to ascertain and nearly impossible to quantify.

P 800 DK01

40

Preferred antipsychotic agents in accordance with the present invention are chlorpromazine, haloperidol, clozapine, loxapine, molindone hydrochloride, thiothixene, olanzapine, ziprasidone, ziprasidone hydrochloride, prochlorperazine, perphenazine, trifluoperazine hydrochloride and risperidone.

5

Anxiety

The combination methods of this invention are also directed to treatment, prevention, amelioration, alleviation, and of conditions of anxiety in a mammal, including a human being. The term anxiety covers generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, social phobia, performance anxiety, post-traumatic stress disorder, acute stress reaction, adjustment disorders, hypochondriacal disorders, separation anxiety disorder, agoraphobia and specific phobias.

15 Preferred antianxiety agents are alprazolam, clonazepam, lorazepam, oxazepam, chlordiazepoxide hydrochloride, diazepam, buspirone hydrochloride, doxepin hydrochloride, hydroxyzine pamoate and clonazepam.

20 Further conditions of individual capable of being treatable in accordance with the present invention are bulimia nervosa, male erectile dysfunction, female sexual dysfunction, thyroid cancer, breast cancer, amelioration of ischemic nerve or muscle damage, as well as systemic lupus erythematosus.

25 The above medicaments are administered in pharmaceutically effective amounts, i.e. an administration involving a total amount of each active component of the medicament or pharmaceutical composition or method that is sufficient to show a meaningful patient benefit.

Examples

30

Example 1

Competition binding assays

Transfected COS-7 cells were transferred to culture plates one day after transfection at a density of 1×10^5 cells per well aiming at 5 - 8 % binding of the radioactive li-

P 800 DK01

41

gained. Two days after transfection competition binding experiments were performed for 3 hours at 4°C using 25 pM of ^{125}I -ghrelin (Amersham, Little Chalfont, UK). Binding assays were performed in 0.5 ml of a 50 mM Hepes buffer, pH 7.4, supplemented with 1 mM CaCl_2 , 5 mM MgCl_2 , and 0.1 % (w/v) bovine serum albumin, 40 $\mu\text{g}/\text{ml}$ bacitracin. Non-specific binding was determined as the binding in the presence of 1 :M of unlabeled ghrelin. Cells were washed twice in 0.5 ml of ice-cold buffer and 0.5-1 ml of lysis buffer (8 M Urea, 2 % NP40 in 3 M acetic acid) was added and the bound radioactivity was counted. Determinations were made in duplicate. Initial experiments showed that steady state binding was reached with the radioactive ligand under these conditions.

Example 2

Receptor activation assays

One simple measure of the ability of a ghrelin like compound to activate the ghrelin receptor is to measure its EC₅₀, i.e. the dose at which the compound is able to activates the signalling of the receptor to half of the maximal effect of the compound. The ghrelin receptor can either be expressed endogenously on primary cells cultures, for example pituitary cells, or heterologously expressed on cells transfected with the ghrelin receptor. Whole cell assays or assays using membranes prepared from either of these cell types can be used depending on the type of assay.

As the ghrelin receptor is generally believed to be primarily coupled to the Gq signalling pathway, any suitable assay which monitor activity in the Gq/G11 signalling pathway can be used, for example:

- 1) an assay measuring the activation of Gq / G11 performed for example by measurement of GTP_GS binding combined with, e.g., anti-G α -q or -11 antibody precipitation in order to increase the signal to noise ratio. This assay may also detect coupling to other G-proteins than Gq/11.
- 2) An assay which measure the activity of phospholipase C (PLC) one of the first down-stream effector molecules in the pathway, for example by measuring the accumulation of inositol phosphate which is one of the products of PLC.

35

P 800 DK01

42

- 3) More down stream in the signalling cascade is the mobilization of calcium from the intracellular stores

4) Further more down stream signalling molecules such as the activity of different kinds of MAP kinases (p38, jun, ect.), NF- κ -B translocation and CRE driven gene transcription may also be measured.

5) Alternatively binding of fluorescently tagged arrestin to the activated ghrelin receptor may also be used.

10 Example 3

Synthetic production of ghrelin-like compound

Amino acid derivatives and synthesis reagents, were obtained from commercial sources. Peptide chain extension was performed by mainly using Applied Biosystems 433A synthesizer produced by Perkin Elmer, and a protected peptide derivative-resin was constructed by the Boc or Fmoc method. The protected peptide resin obtained by the Boc method was deprotected with anhydrous hydrogen fluoride (HF) in the presence of p-cresol thereby releasing the peptide, which was then purified. The protected peptide resin obtained by the Fmoc method was deprotected with trifluoroacetic acid (TFA) or dilute TFA containing various scavengers, and the released peptide was purified. Purification was performed in reversed phase HPLC on a C4 or C18 column. The purity of the purified product was confirmed by reverse phase HPLC, and its structure was confirmed by amino acid composition analysis and mass spectrometry.

The peptide of the present invention is produced by a conventional peptide synthesis method. Specifically, synthesis of acylated or alkylated peptides is exemplified below. Further, human-derived ghrelin (which may be abbreviated hereinafter to hGhrelin) or rat-derived ghrelin (which may be abbreviated hereinafter to rGhrelin) was reacted with trypsin or chymotrypsin or both the enzymes successively to give the following ghrelin fragments: 19. Ghrelin (16-28), 20. hGhrelin (1-15), 21. rGhrelin (1-15), 23. hGhrelin (1-11), 24. rGhrelin (1-11), 25. Ghrelin (1-10), 26. Ghrelin (1-9), 27. Ghrelin (1-8), and 30. Ghrelin (1-4). Then, these fragments were isolated by analytical HPLC and measured for their activity. 41. [N-Acetyl]-Ghrelin (1-10) was .

P 800 DK01

43

prepared in a usual manner by treating Ghrelin (1-10) with N-acetylsuccinimide.
Human and rat ghrelin may also be made by use of a natural material.

Abbreviations

5

HMP resin; 4-hydroxymethyl-phenoxyethyl resin
Fmoc amide resin; 4-(2', 4'-dimethoxyphenyl-Fmoc-aminomethyl) phenoxyacetamido-ethyl resin

10

PAM resin; phenylacetamidomethyl resin
HBTU; 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
TBTU; 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate
HOEt; 1-hydroxybenzotriazole

15

DCC; dicyclohexylcarbodiimide
DIPCl; diisopropylcarbodiimide
TFA; trifluoroacetic acid
DIPEA; diisopropylethylamine
TIPS; triisopropylsilane
Fmoc; fluorenylmethoxycarbonyl

20

Soc; t-butyloxycarbonyl
Trt; trityl
Bu; t-butyl
Pmc; 2,2,5,7,8-pentamethylchroman-6-sulfonyl

25

Pri; propionyl
PhPri; phenylpropionyl
Bzl; benzyl
Bom; benzyloxymethyl
Tos; toluenesulfonyl
Cl-Z; 2-chloro-benzyloxycarbonyl

30

Pls; 2-phenylisopropyl
Mit; 4-methyltrityl
DMF; N,N-dimethylformamide
NMP; N-methylpyrrolidone
DMAP; 4-dimethylaminopyridine

35

HOSe; N-hydroxysuccinimide

P 800 DK01

44

- Adod; 2-aminododecanoic acid
Alb; 2-aminoisobutylic acid
Ape; 5-aminopentanoic acid
Cha; cyclohexylalanine
5 Dap; 2, 3-diaminopropionic acid
Nal; naphthylalanine
Nle; norleucine

Protecting amino acids used in synthesis

10

Fmoc method:

- Boc-Gly, Fmoc-Gly, Fmoc-Ser (Bu), Fmoc-Ser (Trt), Fmoc-Glu (OBu), Fmoc-His (Boc), Fmoc-Gln (Trt), Fmoc-Arg (Pmc), Fmoc-Lys (Boc), Fmoc-Pro, Fmoc-Leu, 15 Fmoc-Ala, Fmoc-Val, Fmoc-Phe, Fmoc-Phe, Fmoc-Ser (n-C8H17), Fmoc-Ser (n-C8H17), Fmoc-Cys (n-C8H17), Fmoc-Asp (OPis), Fmoc-Ser (Bzl), Fmoc-Cys (Trt), Fmoc-Dap (Octanoyl), Fmoc-2-Nal, Fmoc-2-Nal, Fmoc-Nle, Fmoc-Lys (Mtt), Fmoc-Alb-OH, Fmoc-Asp (O-C7H15)

Boc method:

20

- Boc-Gly, Boc-Ser (Bzl), Boc-Ser (Ac), Boc-Ser (Prt), Boc-Glu (OBzl), Boc-His (Bom), Boc-Gln, Boc-Arg (Tos), Boc-Lys (Cl-Z), Boc-Pro, Boc-Leu, Boc-Ala, Boc-Val, Boc-Phe, Boc-Cys (n-C8H17), Boc-Ape Boc-Ser (n-C8H17)

25 Units used

(a) Analytical HPLC system

- 30 Unit: Shimadzu LC-10A System
Column: YMC PROTEIN-RP (4.6 mm phi x150 mm)
Column temperature: 40 DEG C
Eluent: A linear gradient of from 0 to 50 % acetonitrile for 20 minutes in 0.1% trifluoroacetic acid
Flow rate: 1 mL/min.
35 Detection: UV (210 nm)

P 800 DK01

45

Injection volume: 10 to 100 µl**Preparative HPLC system****5 Unit: Waters 600 Multisolvent Delivery System****Columns:**

YMC-Pack-ODS-A (5 µm, 20 mmx250 mm)

YMC-Pack-PROTEIN-RP (5 µm, C4, 10 mmx250 mm)

10 YMC-Pack PROTEIN-RP (5 µm, C4, 20 mmx250 mm)

YMC PROTEIN-RP (4.6 mm phi x150 mm)

Eluent: A suitable linear gradient of acetonitrile concentration in 0.1 % trifluoroacetic acid**15 Flow rate: 10 mL/min. (for the column of an inner diameter of 20 mm), 3 mL/min. (for the column of an inner diameter of 10 mm), 1 mL/min. (for the column of an inner diameter of 4.6 mm) Detection: 210 nm, 260 nm****Injection: 10 to 2000 µl (2000 µl or more was injected via a pump)****(c) Mass spectrometer****20****Unit: Finnigan MAT TSQ700****Ion source: ESI****Detection ion mode: Positive****Spray voltage: 4.5 KV****25 Capillary temperature: 250 DEG C****Mobile phase: A mixture of 0.2% acetic acid and methanol (1 : 1)****Flow rate: 0.2 mL/min.****Scan range: m/z 300 to 1,600****30 (d) Analysis of amino acid sequence****Unit: Applied Biosystem 477A, 492 model sequencer manufactured by Perkin Elmer****(e) Analysis of amino acid composition****35**

P 800 DK01

46

Unit: L-8500 model amino acid analyzer manufactured by Hitachi,Co., Ltd.

Sample: Unless otherwise specified, the sample was hydrolyzed with 6 M HCl at 110 DEG C for 24 hours in a sealed tube.

5

Example of synthesis of a derivative having acyl serine (Fmoc method, carboxyl-terminal amide derivatives)

hGhrelin: GSS(CO-C7H15)FLSPEHQRVQQRKESKKPPAKLQPR

10

Fmoc-Arg(Pmc)-HMP-resin (403 mg, 0.25 mmol, ABI Co., Ltd) was treated with 20% piperazine for 20 minutes and subjected repeatedly to introduction of Fmoc-amino acid by HBTU/HOBt and elimination of Fmoc by piperazine sequentially to construct Fmoc-Ser(Bu)-Ser(Trt)-Phe-Leu-Ser(tBu)-Pro-Glu(OBu)-His(Boc)-Gln(Trt)-Arg(Pmc)-Val-Gln(Trt)-Gln(Trt)-Arg(Pmc)-Lys(Boc)-Glu(OBu)-Ser(Bu)-Lys(Boc)-Lys(Boc)-Pro-Pro-Ala-Lys(Boc)-Leu-Gln(Trt)-Pro-Arg(Pmc)-resin. After Boc-Gly was finally introduced by DCC/HOBt, the resulting protected peptide resin (1.3 g) was treated with 1 % TFA-5 % TIPS-methylene chloride solution (15 mL) for 30 minutes.

15

The peptide resin was filtrated, washed several times with methylene chloride (30 mL), and washed with 5 % DIEA (10 mL) and then with methylene chloride (30 mL). The resulting de-Trt peptide resin (about 1.3 g) was swollen with NMP (10 mL), and octanoic acid (144.2 mg, 1.0 mmol) and DIPCI (126.2 mg, 1.0 mmol) were added thereto in the presence of DMAP (61.1 mg, 0.5 mmol) and allowed to react for 8

20

hours. The resin was recovered by filtration and washed with NMP and then with methylene chloride, followed by drying under vacuum to give about 1.2 g protected peptide resin wherein the side chain of 3rd serine was octanoylated. To this product was added a de-protecting reagent (10 mL) consisting of 88 % TFA-5 % phenol-2% TIPS-5 % H₂O, and the mixture was stirred at room temperature for 2 hours. The

25

resin was removed by filtration, and the filtrate was concentrated followed by adding ether to the resulting residues to form precipitates. The precipitates were recovered by filtration and dried to give about 550 mg crude peptide. 200 mg of this product was dissolved in 10 mL water and applied to YMC-Pack PROTEIN-RP (C4, 20 mmx250 mm) and eluted with a linear gradient (flow rate: 10 mL/min.) for 60 minutes of from 0 to 54 % acetonitrile in 0.1% trifluoroacetic acid. The desired fractions

30

35

P 800 DK01

47

were collected and lyophilized to give about 120 mg of the desired product.

Example of synthesis of a derivative having acyl serine (Fmoc method, carboxyl-terminal amide compounds)

5

Ghrelin (1-9)-NH₂; GSS(CO-C7H15)FLSPEH-NH₂

Fmoc-amide-resin (403 mg, 0.25 mmol, ABI Co.,Ltd) was treated with 20% piperazine for 20 minutes and subjected repeatedly to introduction of Fmoc-amino acid by HBTU/HOBt and elimination of Fmoc by piperazine sequentially to construct Fmoc-Ser(Bu)-Ser(Trt)-Phe-Leu-Ser(Bu)-Pro-Glu(OBu)-His(Boc)-resin. After Boc-Gly was finally introduced by DCC/HOBt, the resulting protected peptide resin (about 550 mg) was treated with 1 % TFA-5 % TIPS-methylene chloride solution (10 mL) for 30 minutes. The peptide resin was recovered by filtration, washed several times with methylene chloride (30 mL), and washed with 5 % DIEA (10 mL) and then with methylene chloride (30 mL). The resulting de-Trt peptide resin (about 750 mg) was swollen with NMP (10 mL), and octanoic acid (144.2 mg, 1.0 mmol) and DIPEI (126.2 mg, 1 mmol) were added thereto in the presence of DMAP (61.1 mg, 0.5 mmol) and allowed to react for 4 hours. The resin was recovered by filtration and washed with NMP and then with methylene chloride, followed by drying under vacuum to give about 800 mg protected peptide resin wherein the side chain of 3rd serine was octanoylated. TFA (10 mL) was added to this product and stirred at room temperature for 30 minutes. The resin was removed by filtration, and the filtrate was concentrated followed by adding ether to the resulting residues to form precipitates. The precipitates were recovered by filtration and dried to give about 250 mg crude peptide. About 200 mg of this product was dissolved in 10 mL of 30 % aqueous acetic acid and applied to YMC-Pack PROTEIN-RP (C4, 20 mmx250 mm) and eluted with a linear gradient (flow rate: 10 mL/min.) for 60 minutes from 0 to 54 % acetonitrile in 0.1 % trifluoroacetic acid. The desired fractions were collected and lyophilized to give about 150 mg of the desired product.

Example of synthesis of a derivative having acyl serine (Boc method)

[Ser3(Propionyl)]-rGhrelin (1-28):

P 800 DK01

48

GSS(CO-CH2CH3)FLSPEHQKAQQRKESKKPPAKLQPR

Protected rat ghrelin resin (4-28) was constructed from Boc-Arg (Tos)-Pam resin (0.75 g, 0.5 mmol) by Boc chemistry, and Boc-Ser (CO-CH₂CH₃)-OH, Boc-Ser (Bzl)-OH and Boc-Gly-OH were condensed with a half (1.4 g) of the resin. The resulting resin, 1.5 g, was treated with a mixture of HF and p-cresol (8.5 mL : 1.5 mL) at 0 DEG C for 1 hour, and the HF was evaporated. Ether was added to the residues, whereby 671 mg crude peptide was obtained. This sample was dissolved in 50% acetic acid (AcOH) and applied to a preparative column YMC-Pack-ODS-A (5 μm, 20 mmx250 mm) and eluted at a rate of 10 mL/min. by a gradient of from 0 to 96 % acetonitrile concentration in 0.1% TFA solution for 75 minutes. Those fractions containing the desired product were lyophilized to give 135.8 mg crude peptide. A part (0.5 mg) of this product was applied to YMC-A-302 column (C18, 4.6 mmx150 mm) and eluted at a flow rate of 1 mL/min. by a gradient of from 15 to 19% concentration acetonitrile. This purification procedure was repeated and the desired fractions were combined to give 0.41 mg of the desired product.

Other compounds according to the invention may be produced likewise.

20 Example 4

A randomised, single centre, four-period cross-over trial to investigate the absolute bioavailability of iv administered Ghrelin and sc administered Ghrelin at three different single doses in healthy subjects.

25

Objectives:

Primary: To investigate the absolute bioavailability of three different doses of Ghrelin administered as single iv and sc doses.

30

Secondary: 1) To Investigate the dose linearity (dose proportionality) of the ascending doses. 2) To investigate and compare the pharmacodynamic profiles between the treatments. 3) To assess the safety and local tolerability.

Trial Design:

P 800 DK01

49

A randomised, single centre, unbalanced block design, four-period cross-over trial to investigate the absolute bioavailability between iv administered Ghrelin and sc administered Ghrelin at three different single doses in healthy subjects. Three doses will be used for each way of administration: low, medium and high. To reduce the number of dosings to each individual and hence reduce the length of the trial each subject will only receive four doses of the total of six doses, ie. two dose levels administered as iv and sc, respectively. The unbalanced block design will ensure that all three-dose levels will be covered in this way although not all subjects will receive all dose levels. A sufficient washout period will be placed between the individual dosing periods.

Endpoints:**Pharmacokinetics of Ghrelin:**AUC_{0-t}, AUC, C_{max}, t_{max}, t_{1/2}, Cl/f, Vz/f, Cl, Vz, , t_{1/2}, MRT

15

Pharmacodynamics:GH: AUC, C_{max} and t_{max}

Cardiac output, assessment of hunger, food/energy intake, degree of pleasure related to food intake, body mass, energy expenditure, DEXA.

20

Safety:

Safety and local tolerability will be assessed throughout the study by clinical evaluations (physical examination and vital signs), electrocardiography and laboratory tests (hematology and clinical chemistry).

25

Trial population and power calculation:Healthy male subjects, aged 18-45 years with a body mass index (BMI) of 19-26 kg/m² (both inclusive).

30

The primary objective of this study is to investigate the absolute bioavailability of ghrelin administered as iv and sc. An unbalanced block design will be applied to reduce the trial period time and reduce the number of dosings per subject. The number of subjects needed to perform a statistical analysis of absolute bioavailability per dose levels as well as an analysis of dose linearity between doses will be calculated based on existing literature data.

35

24/10 2003 14:09 FAX 33320384

HOIBERG A/S

→ PVS

053 DAB

P 800 DK01

50

Trial products:

Ghelin for iv and sc administration.

P 800 DK01

51

Reference List

1. Kojima M, Hosoda H, Matsuo H, Kangawa K 2001 Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab 12:118-122
- 5 2. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S 2001 A role for ghrelin in the central regulation of feeding. Nature 409:194-198
- 10 3. Bowers CY, Momany F, Reynolds GA, Chang D, Hong A, Chang K 1980 Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology 106:663-667
4. Bowers CY, Momany FA, Reynolds GA, Hong A 1984 On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 114:1537-1545
- 15 5. Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DB, Cheng K, Chan WW, Butler B, Hickey G, . 1995 Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A 92:7001-7005
6. Smith RG, Cheng K, Schoen WR, Pong SS, Hickey G, Jacks T, Butler B, Chan 20 WW, Chaung LY, Judith F. 1993 A nonpeptidyl growth hormone secretagogue. Science 260:1640-1643
7. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevich M, Heavens R, Rigby M, Sirinathsinghji DJ, Dean DC, Melillo DG, Van Der Ploeg LH, . 25 1996 A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273:974-977
8. Smith RG, Van Der Ploeg LH, Howard AD, Feighner SD, Cheng K, Hickey GJ, Wyvratt MJ, Jr., Fisher MH, Nargund RP, Patchett AA 1997 Peptidomimetic 30 regulation of growth hormone secretion. Endocr Rev 18:621-645

P 800 DK01

52

9. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K 1999 Ghre-
lin is a growth-hormone-releasing acylated peptide from stomach. Nature
402:656-660

5

P 800 DK01

53

SEQUENCE LISTING

5 <110> Gastrotech ApS

10 <120> Use of a secretagogue

15 <130> P 800 DK00

20 <160> 3

25 <210> 1
<211> 2830 <212> PRT
<213> Homo sapiens

35 <220>

<221> MOD_RES

P 800 DK01

54

<222> (3)..(3)

<223> Amino acid in position 3 is modified with a fatty acid

5

<400> 1

	Gly Ser Ser Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys
10	1 5 10 15

	Glu Ser Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg
	20 25

15

<210> 2

20

<211> 27

<212> PRT

<213> Homo sapiens

25

<220>

30

<221> MOD_RES

<222> (3)..(3)

<223> Amino acid in position 3 is modified with a fatty acid

35

<400> 2

Gly Ser Ser Phe Leu Ser Pro Glu His Gln Arg Val Gln Arg Lys Glu

P 800 DK01

56

1

5

10

15

Ser Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg

5 20 25

<210> 3

10 <211> 28

<212> PRT

15 <213> Rattus rattus

<220>

20 <221> MOD_RES

<222> (3)...(3)

25 <223> Amino acid in position 3 is modified with a fatty acid

<400> 3

30 Gly Ser Ser Phe Leu Ser Pro Glu His Gln Lys Ala Gln Gln Arg Lys
1 5 10 1535 Glu Ser Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg
20 25

P 800 DK01

56

Claims:

1. Use of a secretagogue compound for the preparation of a medicament for the prophylaxis or treatment of lipodystrophy in an individual in need of such treatment.
- 5 2. The use according to claim 1, wherein the secretagogue is ghrelin or a pharmaceutically acceptable salt thereof.
- 10 3. The use according to claim 1 or 2, wherein the secretagogue is a ghrelin-like compound or a pharmaceutically acceptable salt thereof
wherein the ghrelin-like compound comprises a structure defined by formula I
- 15 $Z^1 - (X^1)_m - (X^2) - (X^3)_n - Z^2$, wherein
 Z^1 is an optionally present protecting group
each X^1 is independently selected from an amino acid, wherein said amino acid
20 is selected from naturally occurring and synthetic amino acids,
- 25 X^2 is any amino acid selected from naturally occurring and synthetic occurring amino acids, said amino acid being modified with a bulky hydrophobic group, preferably an acyl group, or a fatty acid,
- 30 each X^3 is independently selected from an amino acid, wherein said amino acid is selected from naturally occurring and synthetic amino acids,
wherein one or more of X^1 and X^3 optionally may be modified by a bulky hydrophobic group, preferably an acyl group, or a fatty acid,
- 35 Z^2 is an optionally present protecting group.
 m is an integer in the range of from 1-10

P 800 DK01

57

n is 0 or an integer in the range of from 1-35.

4. Use according to any of the preceding claims, wherein m is an integer in the range of from 1-9, such as of from 1-8, such as of from 1-7, such as of from 1-6, such as of from 1-5, such as of from 1-4, such as of from 1-3, such as of from 1-2, such as 2,
5. Use according to any of the preceding claims, wherein X^2 is selected from the group of modified Ser, modified Cys and modified Lys, such as wherein X^2 is modified Ser.
10. Use according to any of the preceding claims, wherein the ghrelin-like compound is selected from a compound of
15. formula II $Z^1 - \text{Gly} - (X^1)_{m-1} - (X^2) - (X^3)_n - Z^2$,
- formula III $Z^1 - \text{Gly} - \text{Ser} - (X^2) - (X^3)_n - Z^2$, and
20. formula IV $Z^1 - \text{Gly} - (X^2) - (X^3)_n - Z^2$.
25. Use according to claim 4, wherein the ghrelin-like compound is having formula III.
8. Use according to any of the preceding claims, wherein $(X^3)_n$ comprises a sequence selected from one or more of the sequences shown below:

Phe Leu Ser Pro Glu His Gln

Phe Leu Ser Pro Glu His

30. Phe Leu Ser Pro Glu

Phe Leu Ser Pro

35. Phe Leu Ser

P 800 DK01

58

Phe Leu**Phe**

5

9. Use according to any of the preceding claims, wherein n is an integer in the range of from 1-25, such as of from 1-24, such as from 1-15, such as of from 1-10, such as of from 10-25, such as of from 10-24, such as of from 15-25, such as of from 15-24,
- 10

10. Use according to any of the preceding claims, wherein $(X^2)_n$ is selected from one or more of the sequences shown below:

15 Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala Lys Leu Gln Pro Arg

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala Lys Leu Gln Pro

20 Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala Lys Leu Gln

25 Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala Lys Leu

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala Lys

30 Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro

35 Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro

P 800 DK01

59

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys

5

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu

10

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln

15

Phe Leu Ser Pro Glu His Gln Arg Val Gln

Phe Leu Ser Pro Glu His Gln Arg Val

20

Phe Leu Ser Pro Glu His Gln Arg

Phe Leu Ser Pro Glu His Gln

Phe Leu Ser Pro Glu His

25

Phe Leu Ser Pro Glu

Phe Leu Ser Pro

30

Phe Leu Ser

Phe Leu

Phe

35

P 800 DK01

60

11. Use according to any of the preceding claims, wherein the acyl group is selected from a C1-C35 acyl group, such as a C1 – C20 acyl group, such as a C1 – C15 acyl group, such as a C6 – C15 acyl group, such as a C6 – C12 acyl group,
5 such as a C8 – C12 acyl group..
12. Use according to any of the preceding claims, wherein the acyl group is selected from the group of C7 acyl group, C8 acyl group, C9 acyl group, C10 acyl group, C11 acyl group, and C12 acyl group.
10
13. Use according to any of the preceding claims, wherein the acyl group is selected from the group of C8 acyl group, and C10 acyl group.
14. Use according to any of the preceding claims, wherein the acyl group is selected from the group of C7 acyl group, C9 acyl group, and C11 acyl group, such as
15 from the group of C9 acyl group and C11 acyl group.
15. Use according to any of the preceding claims, wherein the medicament is in a formulation for subcutaneous administration.
20
16. Use according to claim 15, wherein the formulation comprises the ghrelin-like compound or a pharmaceutically acceptable salt thereof.
17. Use according to any of the preceding claims 14 or 15, wherein the formulation comprises the ghrelin-like compound or a salt thereof as a lyophilisate and the formulation further comprises a solvent, said lyophilisate and said solvent being in
25 separate compartments until administration.
18. Use according to any of the preceding claims 12 or 13, wherein the formulation is a solution of the ghrelin-like compound or a salt thereof.
30
19. Use according to claim 17 or 18, wherein the solvent is saline.
20. Use according to any of the preceding claims, wherein the medicament is ad-
35 ministered prior to or during a meal.

P 800 DK01

61

21. Use according to any of the preceding claims, wherein the medicament is administered in a concentration equivalent to from 10 ng to 10 mg ghrelin per kg bodyweight.

5

22. Use according to claim 21, wherein the medicament is administered in a concentration equivalent to from 0.1 µg to 1 mg ghrelin per kg bodyweight, such as from 0.5 µg to 0.5 mg ghrelin per kg bodyweight, such as from 1.0 µg to 0.1 mg ghrelin per kg bodyweight, such as from 1.0 µg to 50 µg ghrelin per kg bodyweight, such as from 1.0 µg to 10 µg ghrelin per kg bodyweight.

10

23. Use according to any of the preceding claims, wherein the medicament is administered as a bolus prior to or during a meal, said bolus comprising an amount of the ghrelin-like compound or a salt thereof equivalent to from 0.3 µg to 600 mg ghrelin.

15

24. Use according to claim 23, wherein the medicament is administered as a bolus prior to or during a meal, said bolus comprising an amount of the ghrelin-like compound or a salt thereof equivalent to from 2.0 µg to 200 mg ghrelin, such as from 5.0 µg to 100 mg ghrelin, such as from 10 µg to 50 mg ghrelin, such as from 10 µg to 5 mg ghrelin, such as from 10 µg to 1.0 mg ghrelin.

20

25. Use according to any of the preceding claims, wherein the medicament is administered from one to three times daily, each administration being during a meal or at the most 45 minutes prior to a meal, such as at the most 30 minutes prior to a meal, such as at the most 25 minutes prior to a meal, such as at the most 20 minutes prior to a meal, such as at the most 15 minutes prior to a meal, such as at the most 10 minutes prior to a meal, such as at the most 5 minutes prior to a meal.

25

30 26. Use according to claim 25, wherein the medicament is administered three times daily.

35 27. Use according to any of the previous claims, wherein the medicament is administered in combination with another pharmaceutically active substance.

35

P 600 DK01

62

28. Use according to claim 27, wherein said pharmaceutically active substance is selected from one or more of:

leptin, agonists of the renin-angiotensin system, opioid receptor agonists or peroxisome proliferator-activated receptor gamma agonists.

5

29. Use according to claim 27, wherein said pharmaceutically active substance is a growth hormone.

30. Use according to claim 29, wherein said growth hormone is hGH.

10

31. Use according to any of claims 27-30, wherein said individual in need of such treatment is suffering from AIDS, HIV or cancer cachexia.

15

32. Use of a non-acylated ghrelin-like compound, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the prophylaxis or treatment of lipodystrophy in an individual in need of such treatment.

33. The use according to claim 32,

20

wherein the non-acylated ghrelin-like compound comprises a structure defined by formula I

$Z^1 - (X^1)_m - (X^2) - (X^3)_n - Z^2$, wherein

25

Z^1 is an optionally present protecting group

each X^1 is independently selected from an amino acid, wherein said amino acid is selected from naturally occurring and synthetic amino acids,

30

X^2 is any amino acid selected from naturally occurring and synthetic occurring amino acids, said amino acid being optionally modified with a bulky hydrophobic group that is not an acyl group.

P 800 DK01

63

each X^3 is independently selected from an amino acid, wherein said amino acid is selected from naturally occurring and synthetic amino acids,

5 wherein one or more of X^1 and X^3 optionally may be modified by a bulky hydrophobic group that is not an acyl group,

Z^2 is an optionally present protecting group.

10 m is an integer in the range of from 1-10

10 n is 0 or an integer in the range of from 1-35.

15 34. Use according to any of claims 32-33, wherein m is an integer in the range of from 1-9, such as of from 1-8, such as of from 1-7, such as of from 1-6, such as of from 1-5, such as of from 1-4, such as of from 1-3, such as of from 1-2, such as 2,

20 35. Use according to any of claims 32-34, wherein X^2 is selected from the group of Ser, Cys and Lys, such as wherein X^2 is Ser.

20 36. Use according to any of claims 32-35, wherein the non-acylated ghrelin-like compound is selected from a compound of

25 formula II $Z^1 - \text{Gly} - (X^1)_{n-1} - (X^2) - (X^3)_n - Z^2$.

25 formula III $Z^1 - \text{Gly} - \text{Ser} - (X^2) - (X^3)_n - Z^2$, and

30 formula IV $Z^1 - \text{Gly} - (X^2) - (X^3)_n - Z^2$.

30 37. Use according to claim 36, wherein the non-acylated ghrelin-like compound is having formula III.

35 38. Use according to any of claims 32-37, wherein $(X^3)_n$ comprises a sequence selected from one or more of the sequences shown below:

35

P 800 DK01

64

Phe Leu Ser Pro Glu His Gln**Phe Leu Ser Pro Glu His**5 **Phe Leu Ser Pro Glu****Phe Leu Ser Pro****Phe Leu Ser**

10

Phe Leu**Phe**

15

39. Use according to any of claims 32-38, wherein n is an integer in the range of from 1-25, such as of from 1-24, such as from 1-15, such as of from 1-10, such as of from 10-25, such as of from 10-24, such as of from 15-25, such as of from 15-24,

20

40. Use according to any of claims 32-39, wherein $(X^3)_n$ is selected from one or more of the sequences shown below:

25

**Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala Lys Leu Gln Pro Arg**

**Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala Lys Leu Gln Pro**

30

**Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala Lys Leu Gln**

35

**Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala Lys Leu**

P 800 DK01

65

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala Lys

5 Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro

10 Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro
Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys

15 Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys
Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu
Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys
20 Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg
Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln

25 Phe Leu Ser Pro Glu His Gln Arg Val Gln

Phe Leu Ser Pro Glu His Gln Arg Val

Phe Leu Ser Pro Glu His Gln Arg
30 Phe Leu Ser Pro Glu His Gln
Phe Leu Ser Pro Glu His
35 Phe Leu Ser Pro Glu

P 800 DK01

66

Phe Leu Ser Pro

Phe Leu Ser

5

Phe Leu

Phe.

10

41. Use according to any of claims 32-40, wherein the medicament is in a formulation for subcutaneous administration

15

42. Use according to claim 41, wherein the formulation comprises the non-acylated ghrelin-like compound or a pharmaceutically acceptable salt thereof.

20

43. Use according to any of the preceding claims 41 or 42, wherein the formulation comprises the non-acylated ghrelin-like compound or a salt thereof as a lyophilisate and the formulation further comprises a solvent, said lyophilisate and said solvent being in separate compartments until administration.

25

44. Use according to any of the preceding claims 41-43, wherein the formulation is a solution of the non-acylated ghrelin-like compound or a salt thereof.

45. Use according to claim 43 or 44, wherein the solvent is saline.

30

46. Use according to any of claims 32-45, wherein the medicament is administered prior to or during a meal.

47. Use according to any of claims 32-46, wherein the medicament is administered in a concentration equivalent to from 10 ng to 10 mg ghrelin per kg bodyweight.

P 800 DK01

67

48. Use according to claim 47, wherein the medicament is administered in a concentration equivalent to from 0.1 µg to 1 mg ghrelin per kg bodyweight, such as from 0.5 µg to 0.5 mg ghrelin per kg bodyweight, such as from 1.0 µg to 0.1 mg ghrelin per kg bodyweight, such as from 1.0 µg to 50 µg ghrelin per kg bodyweight, such as from 1.0 µg to 10 µg ghrelin per kg bodyweight.

49. Use according to any of claims 32-48, wherein the medicament is administered as a bolus prior to or during a meal, said bolus comprising an amount of the non-acylated ghrelin-like compound or a salt thereof equivalent to from 0.3 µg to 600 mg ghrelin.

50. Use according to claim 49, wherein the medicament is administered as a bolus prior to or during a meal, said bolus comprising an amount of the non-acylated ghrelin-like compound or a salt thereof equivalent to from 2.0 µg to 200 mg ghrelin, such as from 5.0 µg to 100 mg ghrelin, such as from 10 µg to 50 mg ghrelin, such as from 10 µg to 5 mg ghrelin, such as from 10 µg to 1.0 mg ghrelin.

51. Use according to any of claims 32-50, wherein the medicament is administered from one to three times daily, each administration being during a meal or at the most 45 minutes prior to a meal, such as at the most 30 minutes prior to a meal, such as at the most 25 minutes prior to a meal, such as at the most 20 minutes prior to a meal, such as at the most 15 minutes prior to a meal, such as at the most 10 minutes prior to a meal, such as at the most 5 minutes prior to a meal.

52. Use according to claim 51, wherein the medicament is administered three times daily.

53. Use according to any of claims 32-52, wherein the medicament is administered in combination with another pharmaceutically active substance.

54. Use according to claim 53, wherein said pharmaceutically active substance is selected from one or more of:
leptin, agonists of the renin-angiotensin system, opioid receptor agonists or peroxisome proliferator-activated receptor gamma agonists.

P 800 DK01

68

55. Use according to claim 53, wherein said pharmaceutically active substance is a growth hormone.

56. Use according to claim 55, wherein said growth hormone is hGH.

5

57. Use according to any of claims 53-56, wherein said individual in need of such treatment is suffering from AIDS, HIV or cancer cachexia.

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/DK2004/000529

International filing date: 06 August 2004 (06.08.2004)

Document type: Certified copy of priority document

Document details: Country/Office: DK
Number: PA 2003 01570
Filing date: 24 October 2003 (24.10.2003)

Date of receipt at the International Bureau: 08 February 2006 (08.02.2006)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse